Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Wuxi Biologics (Cayman) ( (HK:2269) ) has shared an announcement.
WuXi Biologics (Cayman) Inc. announced that its substantial shareholder, WuXi Biologics Holdings Limited, has entered into a block trade agreement with Morgan Stanley & Co. International PLC to place 82,940,000 existing shares, representing approximately 2.04% of the company’s total issued share capital. This transaction will reduce the shareholding of Biologics Holdings from 14.36% to 12.32%, although it will remain a substantial shareholder. The announcement advises shareholders and potential investors to exercise caution as the placing may or may not proceed.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on providing end-to-end solutions for biologics discovery, development, and manufacturing, catering to the global healthcare market.
YTD Price Performance: 59.45%
Average Trading Volume: 56,602,779
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.9B
Find detailed analytics on 2269 stock on TipRanks’ Stock Analysis page.